Mirabella Financial Services LLP Grows Stock Position in Stryker Corporation $SYK

Mirabella Financial Services LLP increased its stake in shares of Stryker Corporation (NYSE:SYK) by 124.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,248 shares of the medical technology company’s stock after acquiring an additional 5,681 shares during the quarter. Mirabella Financial Services LLP’s holdings in Stryker were worth $3,781,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in Stryker by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock valued at $12,485,012,000 after purchasing an additional 272,828 shares during the last quarter. State Street Corp grew its holdings in shares of Stryker by 1.0% in the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock worth $5,929,765,000 after purchasing an additional 150,204 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares during the period. Norges Bank bought a new stake in Stryker during the 2nd quarter valued at $1,882,173,000. Finally, Legal & General Group Plc boosted its position in Stryker by 4.4% during the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock valued at $851,457,000 after buying an additional 96,662 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 1.0%

Shares of Stryker stock opened at $345.64 on Thursday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 12-month low of $328.23 and a 12-month high of $404.87. The company has a market cap of $132.27 billion, a P/E ratio of 41.15, a PEG ratio of 2.04 and a beta of 0.85. The company’s fifty day simple moving average is $364.43 and its two-hundred day simple moving average is $366.61.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company posted $4.01 EPS. Research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Truist Financial cut their price target on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Robert W. Baird set a $437.00 price objective on shares of Stryker in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. The Goldman Sachs Group set a $399.00 target price on Stryker in a research note on Friday, January 9th. Finally, Piper Sandler restated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Fourteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $427.50.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.